Section Arrow
PBYI.NASDAQ
- Puma Biotechnology
Quotes are at least 15-min delayed:2026/02/23 08:50 EST
Pre Market
Last
 6.83
0 (0.00%)
Bid
6.5
Ask
6.95
High 6.83 
Low 6.82 
Volume 30 
Regular Hours (Closed)
Last
 --
-- (--)
Day High 
-- 
Prev. Close
6.83 
1-M High
-- 
Volume 
-- 
Bid
6.5
Ask
6.95
Day Low
-- 
Open
-- 
1-M Low
-- 
Market Cap 
344.17M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High -- 
52-W Low -- 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.74/0.83
Enterprise Value
367.38M
Balance Sheet
Book Value Per Share
2.29
Cash Flow
Cash Flow Yield
0.13
Income Statement
Total Revenue
230.47M
Operating Revenue Per Share
4.55
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks-------- 
Pre Market 22.4 -0.32 -1.41%
ZVRAZevra Therapeutics-------- 
Pre Market 8.75 -0.05 -0.57%
ZURAZura Bio Limited-------- 
Pre Market 6.08 -0.12 -1.94%
ZNTLZentalis Pharmaceuticals-------- 
Pre Market 2.28 -0.14 -5.79%
ZLABZai Lab Limited-------- 
Pre Market 19.9 -0.14 -0.70%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.